QuidelOrtho Corp
No enriched coverage for $QDEL in the last 7 days.
No SEC Form 4 filings for $QDEL in the last 30 days.
See all $QDEL insider activity →QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the “Credit Agreement”),
QuidelOrtho (QDEL) reported Q2 2026 revenue of $630.9 million, up 1.9% constant-currency, with Labs $382.9 million, Immunohematology $134.2 million, and Point of Care $108.2 million. Adjusted EBITDA was $129.3 million (21% growth). China revenue fell 23.3% constant-currency. Full-year 2026 guidance was lowered to $2.52-$2.60 billion revenue and $540-$560 million adjusted EBITDA, with adjusted EPS $0.65-$0.90.
QuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook despite a Q2 beat. Q2 revenue was $630.9M and adjusted EPS $0.13. Full-year guidance was lowered to $2.52B-$2.6B revenue and adjusted EPS of $0.65-$0.90, with the midpoint below analyst estimates.
Recent QDEL coverage spans earnings, corporate actions and financial news.
Amendment eases leverage covenants and sets lower interest rates, potentially improving liquidity and reducing financing costs.
Guidance reset plus negative cash flow and higher leverage risk likely shifts the market’s valuation toward balance-sheet and China execution risk, despite margin expansion.
The guidance cut is the dominant driver, implying weaker forward demand and/or margin pressure that can extend downside beyond the earnings beat.
If a POC sale materializes near the cited value, it would likely reduce earnings volatility and shift valuation toward a lower EV/EBITDA peer multiple.
Guidance reset is the dominant driver, with offsetting positives from outside-China growth and improved EBITDA margin.
AlphAI scores every news story that mentions QDEL with an AI model for sentiment and relevance, and aggregates insider trades from QuidelOrtho Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the “Credit Agreement”),
2 min readQuidelOrtho (QDEL) reported Q2 2026 revenue of $630.9 million, up 1.9% constant-currency, with Labs $382.9 million, Immunohematology $134.2 million, and Point of Care $108.2 million. Adjusted EBITDA was $129.3 million (21% growth). China revenue fell 23.3% constant-currency. Full-year 2026 guidance was lowered to $2.52-$2.60 billion revenue and $540-$560 million adjusted EBITDA, with adjusted EPS $0.65-$0.90.
7 min readQuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook despite a Q2 beat. Q2 revenue was $630.9M and adjusted EPS $0.13. Full-year guidance was lowered to $2.52B-$2.6B revenue and adjusted EPS of $0.65-$0.90, with the midpoint below analyst estimates.
6 min readMcIntyre Partnerships’ Q2 2026 investor letter discusses QuidelOrtho (NASDAQ:QDEL), a diagnostic testing company. The firm says QDEL could sell its POC division for about $1.5B to deleverage, leaving a RemainCo focused on legacy Ortho. It cites QDEL’s Aug 7 close at $12.28 and claims a 12x EV/EBITDA multiple could imply about $100/share.
4 min readQuidelOrtho (QDEL) reported Q2 revenue of $630.9M vs $618.1M estimates and adjusted EPS of $0.13 vs -$0.05, with adjusted EBITDA $129.3M vs $109.3M. It cut FY guidance: revenue midpoint to $2.56B (from $2.73B), adjusted EPS to $0.78, and EBITDA to $550M. China revenue fell 23% amid IVD pricing uncertainty; respiratory volumes were softer.
6 min readQuidelOrtho (NASDAQ: QDEL) reported Q2 CY2026 revenue of $630.9 million, up 2.8% year on year and above analysts’ estimates, and non-GAAP EPS of $0.13, above consensus. Full-year revenue guidance was $2.56 billion at the midpoint, 5.4% below estimates. The stock fell 21.6% to $12.80 after results, citing China demand headwinds.
4 min readQuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company upda
3 min readQuidelOrtho (QDEL) will report earnings Thursday after the bell. The company missed last quarter’s revenue expectations, with revenue of $619.8M, down 10.5% YoY, and also missed EPS guidance and EPS estimates. For this quarter, analysts expect revenue flat YoY. QDEL is down 2.4% over the past month versus an average peer gain; average analyst price target is $21.33 vs $17.58.
3 min readBiotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.
6 min readQuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. qdel-20260622 0001906324 false 0001906324 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):
3 min read
